Targeting the High Mobility Group Box 3 protein sensitizes chemoresistant ovarian cancer cells to cisplatin from Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin
Year: 2023
Type: other
Abstract: The Supplementary Materials include figures, which show siRNA-mediated depletion of HMGB1, HMGB2 and HMGB3 proteins in U2OS cells (Supplementary Figure 1), expression levels of HMGB3 in human ovarian cancer cells (Supplementary Figure 2), LD50 values determined from cisplatin treatment of the A2780 and the A2780/CP70 cells via MTT assays (Supplementary Figure 3), and a luciferase assay to demonstrate transcriptional repression by HMGB3 (Supplementary Figure 4). In addition, there are 3 tables showing the siRNA sequences and the primer sequences used to measure gene expression levels and used for ChIP assays.
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361846166